Serum MACC-1: a new biomarker for breast cancer
Metrics: PDF 87 views | Full Text 185 views | ?
Meraj Ahmed1 and Mohammad Aslam1
1 Department of Surgery, JN Medical College, Aligarh Muslim University, Aligarh, UP, India
Keywords: serum MACC-1; MACC-1; new biomarker; breast cancer
Received: June 09, 2020 Accepted: October 29, 2020 Published: December 01, 2020
Metastasis-associated in colon cancer-1 (MACC-1) is a newly identified tumor marker, found to express in various normal and cancerous tissue. This study is conducted to evaluate the serum MACC-1 level as a diagnostic marker for breast cancer (BC). Sixty new BC patients were included in this study. Patients who received neoadjuvant chemotherapy or with metastatic disease were excluded. Eighty patients of benign disease were taken as control group. All the patients were females with the mean age of 46.7 ± 10.6 years in study group and 40.2 ± 8.4 years in control group (p = 0.0001). The mean serum MACC-1 level in BC patients was 3.46 ± 1.3 ng/ml which was significantly higher than control mean serum MACC-1 level (1.90 ± 0.2 ng/ml) (p < 0.0001). On ROC analysis, the AUC was 0.98 (p ≤ 0.0001; 95% CI = 0.97–1.0) i.e., a good predictor for breast cancer. At the cut-off value of 2.12 ng/ml, the sensitivity and the specificity of serum MACC-1 were 96.7% and 92.5%, respectively. This study showed that serum MACC-1 can be a potential biomarker for diagnosis and tumor progression in patients with breast cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.